<code id='A5CA28F106'></code><style id='A5CA28F106'></style>
    • <acronym id='A5CA28F106'></acronym>
      <center id='A5CA28F106'><center id='A5CA28F106'><tfoot id='A5CA28F106'></tfoot></center><abbr id='A5CA28F106'><dir id='A5CA28F106'><tfoot id='A5CA28F106'></tfoot><noframes id='A5CA28F106'>

    • <optgroup id='A5CA28F106'><strike id='A5CA28F106'><sup id='A5CA28F106'></sup></strike><code id='A5CA28F106'></code></optgroup>
        1. <b id='A5CA28F106'><label id='A5CA28F106'><select id='A5CA28F106'><dt id='A5CA28F106'><span id='A5CA28F106'></span></dt></select></label></b><u id='A5CA28F106'></u>
          <i id='A5CA28F106'><strike id='A5CA28F106'><tt id='A5CA28F106'><pre id='A5CA28F106'></pre></tt></strike></i>

          Home / fashion / explore

          explore


          explore

          author:entertainment    Page View:9
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In